These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12111106)

  • 1. Rapid biotransformation of satraplatin by human red blood cells in vitro.
    Carr JL; Tingle MD; McKeage MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
    Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
    Pendyala L; Creaven PJ
    Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.
    Carr JL; Tingle MD; McKeage MJ
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):483-90. PubMed ID: 16172904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
    Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
    Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
    Mandal R; Sawyer MB; Li XF
    Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
    Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.
    Allain P; Heudi O; Cailleux A; Le Bouil A; Larra F; Boisdron-Celle M; Gamelin E
    Drug Metab Dispos; 2000 Nov; 28(11):1379-84. PubMed ID: 11038167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
    Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
    Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
    Luo FR; Wyrick SD; Chaney SG
    Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
    Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
    Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on satraplatin: the first orally available platinum anticancer drug.
    Kelland LR
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.